Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aminophylline + diphenhydramine
- Development stage
- Unknown
- Lead developer
- Scotmann Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Scot's Expectorant is a combination pharmaceutical product developed by Scotmann Pharmaceuticals for the treatment of respiratory and allergic conditions. It contains aminophylline, a bronchodilator that works by relaxing bronchial smooth muscle through phosphodiesterase inhibition and adenosine receptor antagonism, and diphenhydramine, a first-generation antihistamine that acts as a competitive antagonist at the H1 receptor. This combination is typically used to alleviate symptoms associated with asthma, bronchitis, and allergic rhinitis where both bronchospasm and allergic inflammation are present. It is currently approved for use.
- Brand names
- Scot's Expectorant
- Other names
- Aminophyllin + Diphenhydramine
02
Targets
ADORA2A (Adenosine A₂A Receptor)ADORA1 (Adenosine receptor A1 subtype)ADORA3 (Adenosine A3 receptor)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)PDE3/4 (Cyclic nucleotide phosphodiesterase 3 and 4)ADORA2B (Adenosine A2B receptor)
Beyond the preview
Go deeper on aminophylline + diphenhydramine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aminophylline + diphenhydramine.